<Anchor>
Johnson & Johnson, an American pharmaceutical company, announced the results of a phase 3 trial of a corona vaccine.
The prevention rate is lower than that of Pfizer, Moder, or vaccine, but it only needs to be hit once and can be stored and distributed even at the temperature of the video, which is expected to speed up the distribution of the vaccine.
This is Kim Jong-won from New York.
<Reporter>
Johnson & Johnson, who has been conducting phase 3 tests with 40,000 people since last September, announced the final results.
Unlike existing Pfizer, Moder, or vaccines, the Johnson & Johnson vaccine, which only needs to be given once, has a protective effect of 72% in the U.S., but is slightly ineffective at 57% in South Africa, where the mutant virus is spreading.
[Paul Stoffle/Johnson & Johnson Chief Research and Development Officer: It was effective in preventing severe patients, and it also prevented deaths from corona and hospitalization.
You can see this effect with just one dose.]
Experts say that the number is lower than that of Pfizer's or Modena's vaccine, which has 95% preventive effect, but the actual performance will be the same.
[Michael Osterholm/Director of the Center for Infectious Disease Research and Policy, University of Minnesota: It can be said that it has the same effect, although it cannot be said to be superior to Modena or Pfizer vaccines.
The advantage of the Johnson & Johnson vaccine is that it is much more stable and can last longer in a regular refrigerator.
It will be the most ideal vaccine.]
Johnson & Johnson plans to apply for emergency use approval next week to the US Food and Drug Administration FDA for final approval early next month.
However, due to the lack of initial supply, some forecasts may take longer to be supplied to countries outside the United States.